
Cardiovascular Systems Net Debt | CSII
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Cardiovascular Systems
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -64.6 M | -68.9 M | - | -53.3 M | -95.2 M | -86.8 M | -60.6 M | -83.8 M | -124 M | -55.3 M | -18 M | -9.02 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -9.02 M | -124 M | -65.4 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical devices industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Cutera
CUTR
|
-140 M | - | -10.19 % | $ 1.99 M | ||
|
EDAP TMS S.A.
EDAP
|
-26.7 M | - | - | $ 162 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
38.7 M | - | - | $ 1.77 B | ||
|
Avinger
AVGR
|
-12.4 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
-77.2 M | - | - | $ 3.31 B | ||
|
Eargo
EAR
|
-97.8 M | - | - | $ 10.2 M | ||
|
LENSAR
LNSR
|
-10.2 M | $ 5.6 | -2.78 % | $ 67 M | ||
|
Allied Healthcare Products
AHPI
|
-3.31 M | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
6.46 M | - | -5.86 % | $ 30.6 M | ||
|
Apollo Endosurgery
APEN
|
-22.5 M | - | - | $ 475 M | ||
|
Aziyo Biologics
AZYO
|
-32.4 M | - | 1.37 % | $ 20.5 M | ||
|
BioSig Technologies
BSGM
|
252 K | - | 37.08 % | $ 85.7 M | ||
|
BIOLASE
BIOL
|
6.1 M | - | -13.19 % | $ 166 K | ||
|
Outset Medical
OM
|
63 M | $ 4.04 | -4.49 % | $ 61.5 K | ||
|
AxoGen
AXGN
|
15.2 M | $ 39.49 | -0.6 % | $ 1.82 B | ||
|
Conformis
CFMS
|
-26.2 M | - | - | $ 16.4 M | ||
|
Insulet Corporation
PODD
|
218 M | $ 163.26 | 3.08 % | $ 11.5 B | ||
|
Quanterix Corporation
QTRX
|
7.4 M | $ 3.67 | -6.38 % | $ 156 M | ||
|
CryoLife, Inc.
CRY
|
230 M | - | -4.14 % | $ 702 M | ||
|
Bruker Corporation
BRKR
|
1.59 B | $ 60.45 | -2.74 % | $ 9.18 B | ||
|
Sintx Technologies
SINT
|
-898 K | $ 1.42 | -6.58 % | $ 3.94 M | ||
|
Soliton, Inc.
SOLY
|
-31.6 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.02 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-2.3 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
5.72 M | - | - | $ 462 M | ||
|
TELA Bio
TELA
|
5.33 M | $ 0.69 | -2.81 % | $ 32.4 M | ||
|
Neovasc
NVCN
|
-51 M | - | - | $ 111 M | ||
|
Dynatronics Corporation
DYNT
|
1.8 M | - | 14.99 % | $ 929 K | ||
|
Tactile Systems Technology
TCMD
|
-75.4 M | $ 27.48 | 0.15 % | $ 629 M | ||
|
TransMedics Group
TMDX
|
-32.3 M | $ 72.26 | 1.59 % | $ 2.46 B | ||
|
IRIDEX Corporation
IRIX
|
-5.23 M | $ 0.89 | -3.38 % | $ 15.1 M | ||
|
Tandem Diabetes Care
TNDM
|
239 M | $ 17.12 | 1.3 % | $ 1.16 B | ||
|
Intersect ENT, Inc.
XENT
|
50.8 M | - | - | $ 955 M | ||
|
Second Sight Medical Products
EYES
|
2.62 M | - | -0.97 % | $ 54.4 M | ||
|
GBS
GBS
|
-4.38 M | - | -0.57 % | $ 7.12 M | ||
|
ClearPoint Neuro
CLPT
|
3.85 M | $ 14.12 | -2.55 % | $ 400 M | ||
|
Viemed Healthcare
VMD
|
-1.01 M | $ 11.77 | 0.86 % | $ 458 M | ||
|
Avanos Medical
AVNS
|
8.7 M | $ 24.99 | 0.04 % | $ 1.16 B | ||
|
Beyond Air
XAIR
|
-5.4 M | $ 5.16 | -5.67 % | $ 42.8 B | ||
|
Invacare Corporation
IVC
|
299 M | - | - | $ 24.7 M | ||
|
Xtant Medical Holdings
XTNT
|
-5.4 M | $ 0.43 | -0.39 % | $ 60 M | ||
|
Cytosorbents Corporation
CTSO
|
11 M | $ 0.36 | -0.39 % | $ 22.4 M | ||
|
NanoVibronix
NAOV
|
-4.11 M | - | - | $ 1.08 M | ||
|
NuVasive
NUVA
|
-238 M | - | - | $ 2.07 B | ||
|
Natus Medical Incorporated
NTUS
|
-64.1 M | - | 1.94 % | $ 1.05 B | ||
|
Nevro Corp.
NVRO
|
93.4 M | - | - | $ 217 M | ||
|
Inogen
INGN
|
-86.3 M | $ 6.15 | -2.69 % | $ 164 M |